RECENT UPDATES IN MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA.

Slides:



Advertisements
Similar presentations
Chest Infections Lawrence Pike.
Advertisements

Yong Lee ICU Registrar John Hunter Hospital
Community Acquired Pneumonia Guidelines 2011 Top 11 Recommendations Michael H. Kim.
What is Pneumonia and How Do I Prevent it?
Antibiotic Therapy. 1 A 90-year-old woman presented to rasool s ED with decreased LOC since two days before the admission, fever and chills. V/s: Bp:100/70.
Outline  Diagnosis of CAP  Site of care?  Tools for risk assessment?  Diagnostic tests needed?  Management of severe CAP ? Community-Acquired Pneumonia:
Nikola Bla ž evi ć Mentor: A. Ž mega č Horvat. - inflammation of the lungs caused by infection - many different causes: bacteria, viruses, fungi, idiopathic.
Pneumonia Why do we need to know about it? Long recognized as a major cause of death, Pneumonia has been studied intensively since late 1800s. Despite.
Pneumonia: nursing management Islamic University Nursing College.
MINOR CRITERIAA RESPIRATORY RATEB _30 BREATHS/MIN PAO2/FIO2 RATIOB _250 MULTILOBAR INFILTRATES CONFUSION/DISORIENTATION UREMIA (BUN LEVEL, _20 MG/DL) LEUKOPENIAC.
Management of Community Acquired Pneumonia ATS/IDSA Guidelines 2006 Mazen Kherallah, MD, FCCP Consultant, Infectious Disease and Critical Care Medicine.
CPC # 2 Infectious Disease October 7, 2008 Lisa L. Maragakis, MD MPH.
Developed by Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: September 2009 Most recently updated: October 2013.
Lower Respiratory Tract Infection. Pneumonia Common with high morbidity and mortality rates. Acute respiratory infection with focal chest signs and radiographic.
IDSA/ATS Guidelines on Community-Acquired Pneumonia in Adults
Pam Charity, MD Cathryn Caton, MD, MS.  Define pneumonia  Review criteria for diagnosis  Review criteria for admission  Review treatment options.
PATIENT TYPEETIOLOGY OutpatientStreptococcus pneumoniae Mycoplasma pneumoniae Haemophilus influenzae Chlamydophila pneumoniae Respiratory viruses* Non-ICU.
Community Acquired Pneumonia Ambulatory Medicine 2.
Management of Neutropenic Fevers in cancer patients Jerry Yu.
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
Outpatient vs. Inpatient Treatment of Community-Acquired Pneumonia
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Bacterial Respiratory Disease Slide Set Prepared.
Plans for Diagnosis and Management of Acute Pyelonephritis.
Plans for Diagnosis of Community Acquired Pneumonia.
PRESENTER: HALIMATUL NADIA M HASHIM SUPERVISOR: DR NIK AZMAN NIK ADIB.
Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2.
Response to foreign body Inflammatory reaction –Localized –Generalized Generalized inflammatory reaction –Infective –Noninfective Sepsis: Generalized inflammatory,
Pneumonia in Immunocompromised Host:- Pneumonia in an immunocompromised host describes a lung infection that occurs in a person whose ability to fight.
Life-Threatening Infections: Diagnosis and Antimicrobial Therapy Selection.
Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2.
 What are the signs to diagnose severe pneumonia?  Enumerate 4 organisms for community acquired pneumonia.
Pneumonia Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Introduction Infection involving the.
Impetigo The best topical agent is mupirocin; other agents, such as bacitracin and neomycin, are less effective. Patients who have numerous lesions or.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
 Community-acquired pneumonia (CAP) is a disease in which individuals who have not recently been hospitalized develop an infection of the lungs (pneumonia).
NYU Medical Grand Rounds Clinical Vignette Benjamin Eckhardt, MD PGY-3 October 6, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Diagnosis, Empiric Management and Prevention of CAP
Risk factors for severe disease from pandemic (H1N1) 2009 virus infection reported to date are considered similar to those risk factors identified for.
Community Acquired Pneumonia (CAP)
Hospital-Acquired Pneumonia
Community Acquired Pneumonia Prof. Adel Khattab, MD, FCCP Prof. & Head Of Pulmonary Medicine Dept. Ain Shams University Advisor of the MOH for Chest Diseases.
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
폐렴으로 오인할 수 있는 폐렴 외 질환 호흡기 내과 R3 최 문 찬.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
Community-Acquired Pneumonia Richard G. Wunderink, M.D., and Grant W. Waterer, M.B., B.S., Ph.D. N Engl J Med 2014;370: R3 김선혜 /Prof. 박명재 1.
PROSPECTIVE COHORT STUDY OF ACUTE PYELONEPHRITIS IN ADULTS: SAFETY OF TRIAGE TOWARDS HOME BASED ORAL ANTIMICROBIAL TREATMENT C. VAN NIEUWKOOP A,*, J.W.
Depart. Of Pulmonology and Critical Care Medicine R4 백승숙.
Community-Acquired PneumoniA
MANAGEMENT OF NEUTROPENIC FEVERS IN CANCER PATIENTS Jerry Yu.
Community Acquired Pneumonia. Definitions Community acquired pneumonia (CAP) – Infection of the lung parenchyma in a person who is not hospitalized or.
Comparison between pathogen directed antibiotic treatment and empiri cal broad spectrum antibiotic treatment in patients with community acquired pneumonia.
Time for first antibiotic dose is not predictive for the early clinical failure of moderate–severe community-acquired pneumonia Eur J Clin Microbial Infect.
Intern Report Tony Hung Modified from presentation by Selim Krim, MD, Assistant Professor at TTUHSC.
Community-Acquired Pneumonia. A 67-year-old woman with mild Alzheimer’s disease who has a 2-day history of Productive cough Fever Increased confusion.
Acute Community Acquired Pneumonia Babak Sayad Associate Professor of Infectious Diseases Department of Infectious Diseases Kermanshah University of Medical.
HAP and VAP Guidelines Update
Pulmonary Diseases Sang-Min Lee Division of Pulmonary and Critical Care Medicine Department of Internal Medicine Seoul National University College of Medicine.
By: Wajidah Abdul-Khabir PGY-2
Pneumonia Salutations:
Dr Asmaa fathy abdellah hassan
PHARMACOTHERAPY III PHCY 510
CAP Irfan Shafi  PGY 1  1885,  Dr. Holtzapple administered oxygen to 16-year-old Pt with pneumonia.
CAP Therapy Babak Sayad Associate Professor of Infectious Diseases
بنام خداوند جان و خرد بنام خداوند جان و خرد.
CLINICAL PROBLEM SOLVING
Ordering Sputum Cultures in Community Acquired Pneumonia
Community Acquired Pneumonia
Empiric antibiotic therapy
Presentation transcript:

RECENT UPDATES IN MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA

INTRODUCTION   Improving the care of patients with (CAP) has been the focus of many different organizations.   CAP, together with influenza, remains the seventh leading cause of death in the United States.   915,900 episodes of CAP occur in adults 65 years of age each year in the US.

INTRODUCTION   Two of the most widely referenced guidelines for management of CAP are those of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS)   In response to confusion regarding differences between their respective guidelines, the IDSA and the ATS convened a joint committee to develop a unified CAP guideline document.

INTRODUCTION  Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community

CLINICAL EVALUATION  cough, fever, pleuritic chest pain, dyspnea and sputum production.  Chest pain occurs in 30 percent of cases, chills in 40 to 50 percent, and rigors in 15 percent.  Other common features are gastrointestinal symptoms (nausea, vomiting, diarrhea), and mental status changes.

CLINICAL EVALUATION  Chest examination reveals audible rales in most patients  one-third have evidence of consolidation  The major blood test abnormality is leukocytosis  Leukopenia can occur

RADIOLOGIC EVALUATION  an infiltrate on plain chest radiograph is considered the gold standard for diagnosing pneumonia  The radiographic appearance of community- acquired pneumonia (CAP) may include lobar consolidation  interstitial infiltrates  cavitation

RADIOLOGIC EVALUATION

Site-of-Care Decisions Hospital admission decision Severity-of-illness scores, such as: - CURB-65 criteria (confusion, uremia, respiratory rate, low blood pressure, age 65 years or greater) - the Pneumonia Severity Index (PSI) can be used to identify patients with CAP who may be candidates for outpatient treatment.

PNEUMONIA SEVERITY INDEX FOR CAP

Site-of-Care Decisions Hospital admission decision PNEUMONIA SEVERITY INDEX FOR CAP PSI riskSite of care I - II Outpatients III Observation unit or with a short hospitalization IV - V Inpatients

Site-of-Care Decisions Hospital admission decision CURB-65 criteria 1- confusion (based on a specific mental test or disorientation to person, place, or time) 2- BUN level > 7 m mol/L (20 mg/dL) 3- respiratory rate > 30 breaths/min 4- low blood pressure (systolic, < 90 mm Hg; or diastolic, < 60 mm Hg) 5- age > 65 years

Site-of-Care Decisions Hospital admission decision CURB-65 score Site of care Outpatients 2 admission (wards) 3 admission (ICU)

Site-of-Care Decisions Hospital admission decision Objective criteria or scores should always be supplemented with physician determination of subjective factors including: - the ability to safely reliably take oral medication - the availability of outpatient support resources.

ICU admission decision Direct admission to an ICU is: required for patients with: - septic shock requiring vasopressors - acute respiratory failure requiring intubation and mechanical ventilation. recommended for patients with: 3 of the minor criteria for severe CAP.

Criteria for severe CAP Minor criteria   Respiratory rate > 30 breaths/min   PaO2/FiO2 ratio < 250   Multilobar infiltrates   Confusion/disorientation   Uremia (BUN level > 20 mg/dL)   Leukopeniac (WBC count, < 4000 cells/mm3)   Thrombocytopenia (platelet count, < 100,000 cells/mm3)   Hypothermia (core temperature, < 36C)   Hypotension requiring aggressive fluid resuscitation Major criteria   Invasive mechanical ventilation   Septic shock with the need for vasopressors PaO2/FiO2 = arterial oxygen pressure/fraction of inspired oxygen

Most common etiologies of CAP OutpatientInpatient (non-ICU)Inpatient (ICU) S. pneumoniae M. pneumoniae Staphylococcus aureus H. influenzaeC. pneumoniaeLegionella species C. pneumoniaeH. influenzaeGram-negative bacilli Respiratory virusesLegionella speciesH. influenzae Aspiration Respiratory viruses

Empirical antimicrobial therapy   the initial treatment for most patients remain empirical   Increasing evidence has strengthened the recommendation for combination empirical therapy for severe CAP.   Only 1 recently released antibiotic has been added to the recommendations: ertapenem, as an acceptable b-lactam alternative for hospitalized patients with risk factors for infection with gram-negative pathogens other than Pseudomonas aeruginosa.

Empirical antimicrobial therapy   Selection of antimicrobial regimens for empirical therapy is based on: prediction of the most likely pathogen(s) 2. 2.knowledge of local susceptibility patterns.   Recommendations are generally for a class of antibiotics rather than a specific drug, unless outcome data clearly favor one drug.

Outpatient treatment 1. Previously healthy and no risk factors for drug-resistant S. pneumoniae (DRSP) infection:   A macrolide (azithromycin, clarithromycin, or erythromycin)   Doxycycline

Outpatient treatment 2. Presence of comorbidities such as chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; or use of antimicrobials within the previous 3 months (in which case an alternative from a different class should be selected):   A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])   A b-lactam plus a macrolide

Outpatient treatment 3. In regions with a high rate (>25%) of infection with high-level (MIC > 16 mg/mL) macrolide-resistant S.pneumoniae consider the use of alternative agents listed above in (2) for any patient, including those without comorbidities.

Inpatient, non-ICU treatment   A respiratory fluoroquinolone   A b-lactam plus a macrolide

Inpatient, ICU treatment A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus either azithromycin or a fluoroquinolone (For penicillin-allergic patients, a respiratory fluoroquinolone and aztreonam are recommended.)

Special concerns If Pseudomonas is a consideration   An antipneumococcal, antipseudomonal b-lactam (piperacillintazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin or levofloxacin (750 mg) or   The above b-lactam plus an aminoglycoside and azithromycin or   The above b-lactam plus an aminoglycoside and an antipneumococcal Fluoroquinolone (for penicillin-allergic patients, substitute aztreonam for above b-lactam)

Special concerns if CA-MRSA is a consideration add vancomycin or linezolid CA-MRSA = community-acquired methicillin-resistant Staphylococcus aureus

Time to first antibiotic dose For patients admitted through the emergency department (ED), the first antibiotic dose should be administered while still in the ED.

Switch from intravenous to oral therapy   hemo-dynamically stable   improving clinically   able to ingest medications   have a normally functioning gastrointestinal tract.

Switch from intravenous to oral therapy Patients should be discharged as soon as they:   clinically stable   no other active medical problems   have a safe environment for continued care. Inpatient observation while receiving oral therapy is not necessary.

Duration of antibiotic therapy   Patients with CAP should be treated for a minimum of 5 days   before discontinuation of therapy patients should be: - afebrile for 48–72 h - have no more than 1 CAP-associated sign of clinical instability

Criteria for clinical stability Heart rate < 100 beats/min   Respiratory rate < 24 breaths/min   Temperature < 37.8C   Systolic blood pressure > 90 mm Hg   Arterial oxygen saturation > 90% or pO2 > 60 mm Hg on room air   Ability to maintain oral intake   Normal mental status

Deterioration or progression Early (<72 h of treatment)   Severity of illness at presentation   Resistant microorganism - Uncovered pathogen - Inappropriate by sensitivity   Metastatic infection - Empyema/parapneumonic - Endocarditis, meningitis, arthritis   Inaccurate diagnosis - PE, aspiration, ARDS - Vasculitis (e.g., SLE)

Deterioration or progression Delayed   Nosocomial superinfection - Nosocomial pneumonia - Extrapulmonary   Exacerbation of comorbid illness   Intercurrent noninfectious disease - PE - Myocardial infarction - Renal failure